Denca designs control system for pharma facility

Published: 3-Mar-2011
Manufacturing Finance Pharmaceutical

Project in Liverpool worth £500,000

UK-based automation and control systems specialist Denca Controls has been commissioned by a UK producer of pharmaceuticals and biotechnology to supply control systems for its new manufacturing facility in Liverpool in a project worth £500,000.

The new plant is being built to meet demand for the pharmaceutical firm’s dialysis substitute, which frees patients from the need to be connected to a dialysis machine for 8 hours at a time, instead enabling blood to be cleaned from the convenience of a portable bag.

Denca, based in Widnes, Cheshire has used its expertise to develop process diagrams, design and manufacture control panels, as well as provide software, programming, installation and commissioning. In total, five Siemens S7300 PLCs will be networked with MP 277 touchscreen HMIs, a Profibus Remote IO and communication.

John Talbot, sales and marketing director at Denca, said: ‘It’s not often in our line of work that you are given the opportunity to help, in however small a way, to improve lives. In this case, it’s hugely rewarding to know that, through the implementation of control systems for this groundbreaking new product, we would ultimately be helping the company to provide patients with a better control system to make their day to day lives a little easier.’

Denca works across a spectrum of industry sectors including automotive, chemical, food and beverage, healthcare and utilities. It provides process control solutions based on custom-designed, fully integrated PLC and HMI software for both mechanical and electrical operations as well as UKAS-traceable calibration and certification services.

See more

You may also like

Manufacturing

Denca is under control at SAFC plant in Scotland

Read more
Will supply full control system for IPB2 facility at Irvine

Trending Articles

  1. FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain
  2. Japanese pharma companies shifting to earlier CDMO outsourcing as peptide complexity increases Neuland Laboratories has reported a notable shift in Japanese pharmaceutical outsourcing patterns during the past 12-24 months, with companies engaging CDMOs earlier in the development cycle
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Britain's biotech potential (part I): world-class science, second-class support? The UK produces top-tier life sciences research, offers favourable conditions for early-stage investment and hosts a growing network of internationally competitive clusters. So why does the capital keep leaving?
  4. UK REACH reform falls short as industry warns of £500m+ compliance bill The UK chemicals industry has condemned the Government's long-awaited response to the UK REACH Alternative Transitional Registration model consultation, arguing it does little to support growth or innovation

Upcoming event

CHEMUK 2026

20–21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Denca is under control at SAFC plant in Scotland

Will supply full control system for IPB2 facility at Irvine
Manufacturing

Almac highlights SDS-PAGE approach for residual protein determination in new white paper

New white paper explores robust analytical method for residual protein detection in biocatalytic API manufacturing
Manufacturing

Reliable, high-performance pump for HPLC and UHPLC

Biotech Fluidics announce the ASI 540 – an affordable, standalone solvent delivery pump - design optimised for liquid chromatography applications
Regulatory

WHO prequalifies Novartis' antimalarial Coartem Baby for treatment of newborns and young infants

The decision allows global procurement of artemether-lumefantrine (also known as Riamet Baby in some countries) for the first time, with Novartis adding that it will make the treatment available on a largely not-for-profit basis in malaria-endemic regions
You need to be a subscriber to read this article.
Click here to find out more.
Finance

Britain's biotech potential (part II): world-class science, second-class support?

In part one, Manufacturing Chemist explored the UK’s world-class science base and early-stage investment appeal. In this second instalment, attention turns to the structural gaps that are limiting its ability to scale
Manufacturing

BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech

The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
Regulatory

FDA grants Orphan Drug Designation to pegrizeprument for prevention of heart transplant rejection

The FDA has granted Orphan Drug Designation to pegrizeprument (VEL-101), a novel monoclonal antibody fragment licensed to Veloxis Pharmaceuticals, for the prevention of heart allograft rejection, following a similar designation granted for liver transplant rejection in January 2026
Subscribe now